LEO Pharma

LEO Pharma appoints new Chief Financial Officer and Executive Vice President


Ballerup, Denmark, August 18, 2022 – LEO Pharma A/S today announced the appointment of Philip Eickhoff as its new Chief Financial Officer (CFO) and Executive Vice President, effective September 15, 2022.

Philip Eickhoff
Philip Eickhoff

Philip joins LEO Pharma from Topsoe where he has been CFO since November 2020. Previously, he was CFO at Atos Medical and before that held various leadership positions with Coloplast, including Regional CFO, North America & Pacific. Philip brings extensive experience across finance, strategy and M&A and has a proven track record of driving business transformation.

Philip has a management consulting background from Bain & Company and attained his M.Sc. in Finance and Accounting from Copenhagen Business School and University of Michigan’s Ross Business School.

“I am confident that Philip will be a strong addition to the Global Leadership Team of LEO Pharma. He has an impressive track record as a global CFO from industry leading organizations and as a highly experienced strategic leader. I look very much forward to working closely with Philip as LEO Pharma goes through the next important steps of transformation,” said Christophe Bourdon, CEO of LEO Pharma.

“Joining LEO Pharma represents a unique opportunity for me to return to the healthcare industry. Also, I am excited about LEO Pharma’s transformational journey ahead supported by the joint ownership of the LEO Foundation and Nordic Capital. I look forward to meeting all my new colleagues and working together to make a real difference for people living with skin conditions,” said Philip Eickhoff.

Philip succeeds Anders Kronborg, who joined LEO Pharma in 2015. Anders has served as CFO and as Interim CEO during his time at LEO Pharma. He will retire from the company to pursue opportunities as a professional board member and advisor. Anders shared his intent to retire with the Chair of the Board of Directors in the Autumn of 2021 to ensure a timely onboarding of a suitable successor who can support LEO Pharma in achieving its long-term ambitions.

“I would like to thank Anders very much for his strong commitment to LEO Pharma over the years and his dedication to supporting the business in helping more people living with skin conditions. I wish him all the best of luck in his future endeavors”, said Christophe Bourdon.


Media Contact
Henrik Heskjaer
Director, Global External Communications
Tel: +45 3140 6180


Philip Eickhoff
Philip Eickhoff

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma


• In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease • The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases the impact that AD has on people, regardless of culture or geography

LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis29.9.2022 07:00:00 CEST | Press release

LEO Pharma and DKSH have entered into an agreement to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia. This agreement both supports LEO Pharma’s strategy of building a simpler and more competitive organization and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.

LEO Pharma presents new Adtralza® safety data in moderate-to-severe atopic dermatitis at the 31st EADV Congress8.9.2022 14:15:00 CEST | Press release

• An interim safety analysis from ECZTEND, an open-label, 5-year extension trial, demonstrated consistent safety from the parent trials for up to 3.5 years of Adtralza® (tralokinumab) treatment in adult patients with moderate-to-severe atopic dermatitis.1 • Exposure-adjusted incidence rates of adverse events of special interest, including conjunctivitis, eczema herpeticum, and skin infections requiring systemic treatment, were generally lower than rates reported during the placebo-controlled period up to Week 16 and declined over time.1

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom